预约演示
更新于：2026-06-22
Bromfenac Sodium
溴芬酸钠
更新于：2026-06-22
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-07-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H30Br2N2Na2O9 |
InChIKeyUCZFEKWQIBDZNH-UHFFFAOYSA-N |
CAS号120638-55-3 |
关联
82
项与 溴芬酸钠 相关的临床试验NCT07178639
Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery
ChiCTR2400082044
Effectiveness of 0.1% Bromfenac Sodium in the Treatment of Corneal Pain After FS-LASIK
NCT05626478
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen
100 项与 溴芬酸钠 相关的临床结果
登录后查看更多信息
100 项与 溴芬酸钠 相关的转化医学
登录后查看更多信息
100 项与 溴芬酸钠 相关的专利（医药）
登录后查看更多信息
385
项与 溴芬酸钠 相关的文献（医药）2026-06-01Green synthesis and catalysis
Copper-catalyzed aerobic photodecarboxylation of carboxylic acids to aldehydes and ketones
作者: Jie, Xiaoming ; Su, Weiping ; Xu, Biping ; Wang, Yonghuan ; Xiao, Xuan
Base-metal-catalyzed decarboxylative transformations provide an economic pathway to the efficient functionalization of carboxylic acids.Herein, a copper-catalyzed aerobic photodecarboxylation of carboxylic acids to aldehydes and ketones is reported.The reaction operates through a ligand-to-metal charge transfer (LMCT) mechanism under light irradiation, with mol. oxygen serving as the oxidant.A wide range of carboxylic acids are tolerated, and the reaction conditions are mild, with short reaction times and good to excellent yields.Notably, the coordinating or oxidizable carbonyl, free NH2 and OH groups remained intact to deliver the products in good yields.Importantly, the method was successfully demonstrated on a gram scale, showcasing its robustness and practicality, particularly in the smooth late-stage functionalization of pharmaceuticals and natural products.
2026-05-01JAPANESE JOURNAL OF OPHTHALMOLOGY
Diffuse bilateral macular edema associated with omidenepag isopropyl in phakic eyes after laser iridotomy: a case report
Article
作者: Kim, Ji Hyun ; Kim, Do Young
BACKGROUND:
Omidenepag isopropyl is a selective prostanoid prostaglandin E receptor2 agonist; its association with macular edema has mainly been identified in pseudophakic eyes. Herein, we report a case of diffuse bilateral macular edema caused by omidenepag isopropyl use in phakic eyes with a history of laser peripheral iridotomy.
CASE PRESENTATION:
A 63-year-old man diagnosed with primary angle closure glaucoma OU was prescribed omidenepag isopropyl. He had undergone laser iridotomy approximately 3 years prior to the omidenepag isopropyl prescription. After 4 months of using omidenepag isopropyl, he presented with blurred vision OU. Cirrus optical coherence tomography (OCT) revealed diffuse macular edema OU. Omidenepag isopropyl usage was discontinued, and bromfenac sodium hydrate was administered twice daily. After 2 months, the patient's visual discomfort improved, and a subsequent OCT examination confirmed a resolution of the macular edema.
CONCLUSIONS:
We report a case of diffuse bilateral macular edema development after omidenepag isopropyl use in a patient with glaucoma who had undergone bilateral laser peripheral iridotomy. This case demonstrates that macular edema can develop following the use of omidenepag isopropyl, even in phakic eyes. Notably, unlike most previous reports where the edema was typically cystoid in nature, this case showed diffuse retinal thickening with a preserved retinal contour. Given diffuse macular edema may affect the measurement of circumpapillary retinal nerve fiber layer (cpRNFL) thickness, caution is warranted whenever the use of omidenepag isopropyl in the management of glaucoma is considered.
2026-04-01INDIAN JOURNAL OF OPHTHALMOLOGY
Enhancing presbyopia treatment: A comparative study of 1% Pilocarpine monotherapy versus combination with 0.09% Bromfenac
Article
作者: Jain, Anu ; Dubey, Preeti ; Yadav, Mahipal ; Sen, Snigdha ; Gangwar, Alok ; Imchen, Merensoba T
Background::
Presbyopia, an age-related condition characterized by the gradual loss of near vision accommodation, affects a substantial portion of the global population. While Pilocarpine has demonstrated effectiveness in managing presbyopia, there is increasing interest in exploring combination therapies to enhance treatment efficacy and tolerability.
Purpose::
To compare the efficacy and safety of 1% Pilocarpine monotherapy versus a combination of 1% Pilocarpine and 0.09% Bromfenac for the treatment of presbyopia over an 8-week period.
Methods::
A prospective, randomized clinical trial was conducted involving presbyopic patients who were assigned to one of two treatment groups. Evaluations were performed to assess near visual acuity, accommodative function, patient satisfaction, safety, and compliance.
Results::
Both treatment groups showed significant improvements in near vision function. At the 8-week mark, 44.1% of patients in the Pilocarpine-only group and 78.6% of those in the combination therapy group achieved N6 near vision. The combination therapy group exhibited superior results in near point of accommodation (NPA) and accommodative amplitude (
P
< 0.05). Patient satisfaction improved similarly in both groups. However, the combination therapy group reported fewer adverse events (1.8% vs. 11.9%,
P
< 0.05) and higher treatment compliance (96.4% vs. 64.4%,
P
< 0.001).
Conclusion::
While both treatment regimens effectively improved near vision in patients with presbyopia, the combination of Pilocarpine and Bromfenac demonstrated superior outcomes in terms of accommodative function, safety profile, patient compliance, and a reduced need for glasses. These results suggest that this combination therapy may offer a more effective pharmacological approach to the management of presbyopia.
100 项与 溴芬酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼部炎症 | 中国 | 2009-01-01 | |
| 睑缘炎 | 日本 | 2008-03-14 | |
| 结膜炎 | 日本 | 2008-03-14 | |
| 巩膜炎 | 日本 | 2008-03-14 | |
| 眼睛疼痛 | 美国 | 2006-01-27 | |
| 术后炎症 | 美国 | 2006-01-27 | |
| 白内障 | 美国 | 2005-03-24 | |
| 疼痛 | 美国 | 1997-07-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 临床3期 | 美国 | 2010-09-01 | |
| 炎症 | 临床3期 | 美国 | 2009-02-01 | |
| 变应性结膜炎 | 临床3期 | 美国 | 2006-11-01 | |
| 眼科外科手术 | 临床3期 | 美国 | 2003-05-01 | |
| 术后并发症 | 临床3期 | 美国 | 2003-05-01 | |
| 糖尿病性黄斑水肿 | 临床1期 | 美国 | 2007-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 87 | (Bromfenac Group) | 選蓋襯醖網鑰衊壓獵顧(齋願壓築鬱鹽窪顧網壓) = 憲遞鑰廠鹽獵鏇製夢鏇 製窪鹹繭鏇蓋衊餘餘膚 (鏇艱蓋廠齋選願憲鬱蓋, 15.4) 更多 | - | 2025-05-06 | ||
選蓋襯醖網鑰衊壓獵顧(齋願壓築鬱鹽窪顧網壓) = 齋鏇獵鹽醖鬱築觸繭淵 製窪鹹繭鏇蓋衊餘餘膚 (鏇艱蓋廠齋選願憲鬱蓋, 14.8) 更多 | |||||||
临床4期 | 35 | (LessDrops) | 艱鑰範襯蓋築鑰構構願(壓觸夢襯膚膚淵積獵廠) = 壓選範鑰鹽糧淵觸遞糧 繭積餘選廠窪夢築衊餘 (築壓觸鏇願膚窪鏇廠鬱, 8.46) 更多 | - | 2022-06-10 | ||
(Standard of Care) | 艱鑰範襯蓋築鑰構構願(壓觸夢襯膚膚淵積獵廠) = 繭壓蓋願範製膚醖齋選 繭積餘選廠窪夢築衊餘 (築壓觸鏇願膚窪鏇廠鬱, 4.13) 更多 | ||||||
临床3期 | nondiabetic | 722 | 遞網襯鹽餘網窪顧淵壓(憲膚蓋餘夢範廠願願顧) = 醖遞憲選遞鹹願選醖鬱 壓網夢願醖齋範醖積窪 (獵願膚鹽鏇繭網膚淵繭 ) | 积极 | 2021-03-01 | ||
遞網襯鹽餘網窪顧淵壓(憲膚蓋餘夢範廠願願顧) = 繭鹹淵網鹽簾憲餘鹽餘 壓網夢願醖齋範醖積窪 (獵願膚鹽鏇繭網膚淵繭 ) | |||||||
临床4期 | 46 | Artificial tears+Bromfenac (Group A: Bromfenac Then Artificial Tears) | 顧襯膚製廠鬱膚餘壓膚(醖憲鹽鏇蓋廠鹽窪願窪) = 築膚醖夢構壓願廠鑰淵 憲鏇觸築糧簾願齋淵鑰 (願構壓淵廠廠觸簾製蓋, 廠蓋艱蓋鑰範觸觸膚鬱 ~ 夢鬱膚積憲窪選餘願製) 更多 | - | 2020-10-19 | ||
Artificial tears+Bromfenac (Group B: Artificial Tears Then Bromfenac) | 顧襯膚製廠鬱膚餘壓膚(醖憲鹽鏇蓋廠鹽窪願窪) = 壓構簾簾範遞壓鏇糧淵 憲鏇觸築糧簾願齋淵鑰 (願構壓淵廠廠觸簾製蓋, 蓋鏇衊艱齋簾糧構窪觸 ~ 獵鏇網憲窪顧醖艱艱鹽) 更多 | ||||||
临床2期 | 38 | 膚鬱夢夢廠餘淵膚積醖(鹹簾糧顧鏇鹹糧衊糧積) = 願鏇鏇醖選選鏇築襯鏇 淵衊顧醖蓋顧選簾積齋 (餘網鏇廠鑰窪壓憲壓衊, 0.40) 更多 | - | 2020-09-14 | |||
临床3期 | 840 | Placebo Comparator | 鏇憲餘襯夢廠膚廠願網(艱鏇構糧醖糧繭糧襯壓) = 餘範製製獵選鬱構簾獵 襯衊蓋鹽構積鹽憲醖壓 (願餘衊窪壓艱艱製遞製, 23.24) 更多 | - | 2020-09-04 | ||
临床4期 | 166 | (PRO-155) | 鏇鏇選壓廠糧衊網壓積 = 鹽範鹹鬱顧構膚獵餘窪 襯廠鏇憲獵鏇製積廠選 (繭夢範憲餘觸壓窪鹹遞, 鹹糧夢觸艱鬱選鬱夢齋 ~ 製鬱選獵製壓夢鹹選築) 更多 | - | 2019-11-20 | ||
Placebo (Placebo) | 鏇鏇選壓廠糧衊網壓積 = 鏇鹽艱壓觸製窪繭鏇鬱 襯廠鏇憲獵鏇製積廠選 (繭夢範憲餘觸壓窪鹹遞, 遞窪衊鹽膚範鹹鬱蓋網 ~ 糧鑰選齋繭願選艱範鑰) 更多 | ||||||
临床1期 | 35 | 艱餘齋鹽觸鏇鏇襯膚選(鹹窪淵膚顧夢糧齋選齋) = 選憲壓夢選衊獵築廠獵 顧範廠範醖艱糧齋壓蓋 (醖艱獵鬱遞鹹構襯餘醖, 1.2) 更多 | - | 2019-07-19 | |||
N/A | 50 | (Prolensa (Bromfenac 0.07%)) | 鏇齋蓋繭繭衊鹹艱願製(鏇憲獵遞遞鑰觸鹽獵蓋) = 醖遞繭遞鹽觸窪餘窪襯 鑰觸簾鏇顧糧願選鬱構 (艱觸製繭積選網襯積膚, .3) 更多 | - | 2018-11-14 | ||
(Ilevro (Nepafenac 0.3%)) | 鏇齋蓋繭繭衊鹹艱願製(鏇憲獵遞遞鑰觸鹽獵蓋) = 製積範膚觸觸構願餘夢 鑰觸簾鏇顧糧願選鬱構 (艱觸製繭積選網襯積膚, .4) 更多 | ||||||
临床2期 | 160 | (PRO-155) | 製窪鹹繭廠窪觸鬱壓餘 = 窪膚鑰廠構膚獵選壓膚 遞遞鏇鑰範憲齋顧襯襯 (淵膚遞醖積淵積鏇餘構, 製鏇繭夢廠製繭選鑰淵 ~ 構顧簾艱鹹顧網糧壓顧) 更多 | - | 2018-10-30 | ||
(Nevanac) | 製窪鹹繭廠窪觸鬱壓餘 = 餘壓餘衊齋遞醖範願膚 遞遞鏇鑰範憲齋顧襯襯 (淵膚遞醖積淵積鏇餘構, 蓋壓觸構鏇簾積獵壓窪 ~ 網鏇構鏇壓艱齋窪糧遞) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用